When we see patients in our offices with metastatic colon cancer which is confined to the peritoneal cavity and the histology of the cancer shows mucinous carcinoma, we consider not only chemotherapy but also think about specialized surgery to remove the cancer in the abdomen and combine this with hyperthermia and chemotherapy given directly into the cavity during surgery.

Why is that? Read the rest of this entry »

Genomic Health has commercialized a new test which has been shown to be associated with risk of tumor recurrence for stage II colon cancer. The test came on the market in January of 2010.

I wanted to review with you the limitations of this test, which is  not as good by far as the test they have developed for breast cancer. Read the rest of this entry »

Every year in the month of March we celebrate our patients during a reception at USC.

We invite them for food and wine in the Norris lobby which we convert into a party space. We invite patients and physicians to talk about their experiences and about new developments at our center and the progress we have made in the last year. Read the rest of this entry »

In this month we don’t want to only raise awareness about prevention of colon cancer. We should be aware of the significant progress we have made in the last 10 years treating it.

With the introduction of irinotecan, oxaliplatin, bevacizumab, and cetuximab, overall survival has tripled to more than two years; but this does not tell us the whole story. In the past patients with metastatic disease all died from their disease. This is not true any longer.

With more active therapies, we have cured more and more patients, particularly those whose cancer has only spread to the liver. There are increasing reports that this is also true for lesions found in one site in the lung. Read the rest of this entry »

At ASCO in June 2009  a study was presented showing potential benefit of a novel inhibitor of AKT and MAPK in patients with metastatic colon cancer in second and third line chemotherapy.  An update at the 2010 ASCO GI meeting in January further confirmed these promising results.

This was a randomized phase II study comparing Xeloda alone versus a combination of Perifosine and Xeloda. Read the rest of this entry »